2046.5000 27.90 (1.38%)
NSE Sep 25, 2025 12:52 PM
Volume: 763.8K
 

ICICI Securities Limited
Glenmark Pharmaceuticals’ (Glenmark) subsidiary Ichnos Glenmark Innovation (IGI) has out-licensed its oncology asset ISB 2001 to Abbvie in a deal valued at USD 1.925bn, including USD 700mn upfront, USD 1.225bn in milestones and tiered doubledigit royalty on net sales.
Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 1648.3
More from Glenmark Pharmaceuticals Ltd.
Recommended